Loading organizations...
§ Private Profile · 15 Crosby Drive Bedford, MA 01730
Ocular Therapeutix is a technology company.
Ocular Therapeutix develops and commercializes innovative ophthalmic therapies designed to treat diseases and conditions of the eye, with a primary focus on retinal disorders. The company leverages a proprietary hydrogel-based drug delivery platform to enable sustained-release medication, aiming to improve patient outcomes and reduce the burden of frequent treatments. This technology allows for localized and prolonged therapeutic effects directly within the eye.
The company was co-founded by Amarpreet S. Sawhney and Farhad Khosravi in September 2006. Their foundational insight centered on addressing the significant challenge of patient adherence and treatment efficacy in chronic eye diseases, recognizing the need for less frequent and more potent therapeutic interventions delivered via advanced biomaterials. Sawhney, a known innovator in the field of biomaterials, brought significant expertise to the venture.
Ocular Therapeutix’s products primarily serve patients suffering from chronic and debilitating ophthalmic conditions, such as wet age-related macular degeneration and diabetic retinopathy. The company’s long-term vision is to transform the treatment landscape for these diseases, providing solutions that offer durable efficacy, enhanced safety, and a significantly improved quality of life for patients by minimizing the need for repetitive, invasive procedures.
Ocular Therapeutix has raised $88.8M across 6 funding rounds.
Ocular Therapeutix has raised $88.8M in total across 6 funding rounds.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company developing, manufacturing, and commercializing innovative therapies for eye diseases using its proprietary hydrogel platform technology.[1][2] It serves patients with conditions like retinal diseases (e.g., wet age-related macular degeneration or wet AMD, non-proliferative diabetic retinopathy or NPDR, diabetic macular edema or DME), glaucoma, ocular hypertension, post-surgical pain, and inflammation, addressing unmet needs such as frequent injections and poor treatment adherence.[2][5][6] Key products include the FDA-approved DEXTENZA (dexamethasone insert) for post-surgical ocular pain and inflammation, and ReSure Sealant for sealing corneal incisions after cataract surgery; its pipeline features AXPAXLI (OTX-TKI, axitinib hydrogel) in Phase 3 for wet AMD and DR, OTX-TIC (travoprost intracameral hydrogel) in Phase 2 for glaucoma, and earlier-stage intravitreal assets.[1][6][7][9] The company shows strong growth momentum with a sharpened focus on retinal diseases, leveraging ELUTYX hydrogel for sustained-release delivery to reduce injection frequency to 1-2 per year while improving outcomes.[2][3][8]
Founded in 2006, Ocular Therapeutix pioneered hydrogel-based drug delivery for ophthalmology, starting with ReSure Sealant, FDA-approved for corneal incisions post-cataract surgery.[1][4] Early traction came from licensing its proprietary hydrogel technology across specialties like orthopedics, neurosurgery, and cardiology, treating millions of patients and building deep expertise.[4] Pivotal moments include advancing DEXTENZA through Phase 3 to approval for post-surgical use, and evolving its pipeline with travoprost inserts (OTX-TP in Phase 3 for glaucoma) and intravitreal depots.[1][4] Under leadership like Executive Chairman, President, and CEO Pravin Dugel, MD, the company has recently refocused on retinal diseases, targeting wet AMD as priority amid rising needs in NPDR and DME.[2]
Ocular Therapeutix rides the wave of sustained-release drug delivery in ophthalmology, countering burdens of frequent anti-VEGF injections for retinal diseases amid aging populations and diabetes epidemics (e.g., 3M Americans/80M worldwide with glaucoma; millions untreated in NPDR/DME).[6][7][8] Timing aligns with demand for less invasive therapies preserving vision without compliance issues, fueled by market forces like rising wet AMD prevalence and regulatory nods for hydrogels (e.g., DEXTENZA approval).[1][2] It influences the ecosystem by licensing tech broadly, advancing intravitreal depots for retinal blinding conditions, and partnering (e.g., Regeneron), potentially expanding options beyond short-acting injectables.[4][5]
Ocular Therapeutix is poised for breakthroughs with AXPAXLI in Phase 3 for wet AMD/DR, potentially redefining retinal care via 1-2 yearly injections, alongside OTX-TIC Phase 2 data for glaucoma.[6][7][8] Trends like AI-optimized trials, biologics evolution, and global eye disease surges will shape its path, with expansion into NPDR/DME unlocking massive markets.[2][5] Its influence may grow through approvals, partnerships, and hydrogel scalability, solidifying its role in transforming eye therapies from burdensome to sustainable—building on its hydrogel legacy to combat irreversible blindness.[1][3]
Ocular Therapeutix has raised $88.8M across 6 funding rounds. Most recently, it raised $24.0M Series D in June 2013.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 1, 2013 | $24M Series D | — | Ascension Ventures, Versant Ventures | Announced |
| Jan 28, 2013 | $23.8M Series D Plus | — | Ascension Ventures, Polaris Partners, Sparta, SV Health Investors, Versant Ventures | Announced |
| Feb 1, 2011 | $14M Series D | Ascension Ventures | Acorn Bioventures, Flagship Ventures, Polaris Partners, Versant Ventures | Announced |
| Jan 1, 2011 | $6M Series C | — | Acorn Bioventures, Flagship Ventures, Polaris Partners, Versant Ventures | Announced |
| Jun 1, 2009 | $15M Series C | — | Acorn Bioventures, Flagship Ventures, Polaris Partners, Versant Ventures | Announced |
| Mar 1, 2008 | $6M Series B | — | Versant Ventures | Announced |
Ocular Therapeutix has raised $88.8M in total across 6 funding rounds.
Ocular Therapeutix's investors include Ascension Ventures, Versant Ventures, Polaris Partners, Sparta, SV Health Investors, Acorn Bioventures, Flagship Ventures.